Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine

Journal of Medical Virology

Volumn 59, Issue 4, 1999, Pages 507-511

  Izopet, J ^a   Bicart See, A ^a   Pasquier, C ^a   Sandres, K ^a   Bonnet, E ^a   Marchou, B ^a   Puel, J ^a   Massip, P ^a  

^a CHU PURPAN   (France)

Author keywords

HIV resistance; Stavudine plus didanosine; Zidovudine mutations

Indexed keywords

DIDANOSINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CROSS RESISTANCE; DRUG ACTIVITY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE; ZIDOVUDINE;

EID: 0032693960     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199912)59:4<507::AID-JMV14>3.0.CO;2-C     Document Type: Article

References (16)

1. Brun-Vézinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ, the National Virology Groups and the Delta Virology Working Group and Coordinating Committee. 1997. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 350:983-990.
2. Carpenter CJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. 1998. Anti-retroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 280: 78-86.
3. Coakley E, Gillis J, Hammer S. 1999. Mutations in the reverse transcriptase genome of HFV-1 isolates derived from subjects treated with Didanosine and Stavudine in combination. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January 31-February 4, 1999.
4. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, De-Gruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, et al. 1995. Zidovudine resistance and HIV-1 desease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 122:401-408.
5. Descamps D, Yvon A, Valantin M, Collin G, Cécille A, Coutellier A, Damond F, Mouroux M, Bonmarchand M, Bossi P, Matheron S, Huraux J, Costagliola D, Katlama C, Brun-Vézinet F, Calvez V. 1998. Phenotypic and genotypic analysis of experienced patients (zidovudine, zidovudine/didanosine, zodivudine/zalcitabine) treated with stavudine/lamivudine combination (ALTIS 2 trial). Lake Maggiore, Italy: Second International Workshop on Drug Resistance and Treatment Strategies. 24-27 June 1998.
6. Gazzard B, Moyle G on behalf of the BHIVA Guidelines Writing Committee. 1998. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 352:314.
7. Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J, Eastman S. 1995. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J Virol 69:3510-3516.
8. Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR for the AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. 1995. Prevalence and clinical significance of Zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 171:1172-1179.
9. Kwok S, Higushi R. 1989. Avoiding false positives with PCR. Nature 339:237-238.
10. Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JMA, Pennington KN, St Clair MH, The Protocol 34 225-02 Collaborative Group. 1996. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′, 3′-dideoxycytidine combination therapy. J Virol 70:5922-5929.
11. Phiboonbanakit D, Lloyd J, Khoo S, Wilkins E, Maher B, Barry M, Back D. 1999. Quantification of D4T Triphosphate (d4TTP) in ZDV naive and ZDV experienced HIV infected individuals by an enzymatic assay. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January 31-February 4, 1999.
12. Raffi F, Reliquet V, Auger S, Besnier J, Chennebault J, Billaud E, Michelet C, Perre P, Lafeuillade A, May T, Billaudel S. 1998. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients. AIDS 12:1999-2005.
13. Richman DD, Meng TC, Spector SA, Fischl MA, Resnick L, Lai S. 1994. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 7:135-138.
14. Schinazi RF, Larder BA, Mellors JW. 1996. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 4:95-107.
15. Schooley RT, Ramirez-Ronda C, Lange JMA, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder B, St. Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF and the Wellcome Resistance Study Collaborative Group. 1996. Virologie and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 173:1354-1366.
16. Segondy M, Izopet J, Pellegrin I, Montes B, Dumon B, Pasquier C, Peeters M, Fleury HJA, Puel J, Reynes J. 1998. Comparison of the Quantiplex HIV-1 RNA 2.0 assay with the Amplicor HIV-1 Monitor 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine- didanosine combination therapy. J Clin Microbiol 36:3392-3395.